Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults

(2022) Pierre‐François Meyer et al.   ANNALS OF NEUROLOGY

Associating Alzheimer’s disease pathology with its cerebrospinal fluid biomarkers

(2022) Claire Bridel et al.   BRAIN

Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

(2022) Denis S. Smirnov et al.   ACTA NEUROPATHOLOGICA

CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design

(2022) Alexis Moscoso et al.   Alzheimers & Dementia

The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography

(2021) Justin S. Sanchez et al.   Science Translational Medicine

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

(2021) Adam M. Brickman et al.   Alzheimers & Dementia

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

(2021) N. J. Ashton et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework

(2021) E. E. Wolters et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

(2021) A. Leuzy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies

(2021) Che-Wei Chang et al.   SCIENCE

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease

(2021) Ming Lu et al.   JAMA Neurology

Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research

(2021) Christina M. Moloney et al.   Alzheimers & Dementia

Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease

(2021) Rik Ossenkoppele et al.   Alzheimers & Dementia

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory

(2021) David Berron et al.   BRAIN

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

(2021) Niklas Mattsson‐Carlgren et al.   EMBO Molecular Medicine

Four distinct trajectories of tau deposition identified in Alzheimer’s disease

(2021) Jacob W. Vogel et al.   NATURE MEDICINE

Antisense technology: an overview and prospectus

(2021) Stanley T. Crooke et al.   NATURE REVIEWS DRUG DISCOVERY

Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe

(2021) Paul A Yushkevich et al.   BRAIN

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

(2021) Rik Ossenkoppele et al.   EMBO Molecular Medicine

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

(2021) Elisabeth H Thijssen et al.   LANCET NEUROLOGY

Biomarkers for neurodegenerative diseases

(2021) Oskar Hansson   NATURE MEDICINE

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

(2021) Sebastian Palmqvist et al.   NATURE MEDICINE

Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays

(2021) Antoine Leuzy et al.   NEUROLOGY

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

(2021) Nicholas C. Cullen et al.   Nature Communications

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

(2021) Alberto Lleó et al.   Nature Communications

Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications

(2021) Irina A. Pikuleva et al.   Frontiers in Aging Neuroscience

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

(2021) Michelle M. Mielke et al.   JAMA Neurology

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

(2021) Rik Ossenkoppele et al.   JAMA Neurology

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231

(2021) Sherif Bayoumy et al.   Alzheimers Research & Therapy

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

(2021) Antoine Leuzy et al.   JAMA Neurology

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease

(2020) David Berron et al.   BRAIN

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

(2020) Adam S. Fleisher et al.   JAMA Neurology

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

(2020) Antoine Leuzy et al.   JAMA Neurology

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

(2020) Tharick A Pascoal et al.   BRAIN

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

(2020) Thomas K. Karikari et al.   Alzheimers & Dementia

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

(2020) Alexis Moscoso et al.   BRAIN

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease

(2020) Kanta Horie et al.   BRAIN

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

(2020) Niklas Mattsson-Carlgren et al.   Nature Communications

Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons

(2019) Rik van der Kant et al.   Cell Stem Cell

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

(2019) Clifford R Jack et al.   BRAIN

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

(2019) Rik van der Kant et al.   NATURE REVIEWS NEUROSCIENCE

Longitudinal tau PET in ageing and Alzheimer’s disease

(2018) Clifford R Jack et al.   BRAIN

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway

(2018) Mengchen Lu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Tau-targeting therapies for Alzheimer disease

(2018) Erin E. Congdon et al.   Nature Reviews Neurology

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Mechanisms of Cell-to-Cell Transmission of Pathological Tau

(2018) Garrett S. Gibbons et al.   JAMA Neurology

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

(2017) Sarah L. DeVos et al.   Science Translational Medicine

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

(2016) Rik Ossenkoppele et al.   BRAIN

Neuronal activity enhances tau propagation and tau pathology in vivo

(2016) Jessica W Wu et al.   NATURE NEUROSCIENCE

PET Imaging of Tau Deposition in the Aging Human Brain

(2016) Michael Schöll et al.   NEURON

Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology

(2015) Marie-Anne Burlot et al.   HUMAN MOLECULAR GENETICS

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

(2015) Natura Myeku et al.   NATURE MEDICINE

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

(2014) Tara L. Spires-Jones et al.   NEURON

Antisense Reduction of Tau in Adult Mice Protects against Seizures

(2013) S. L. DeVos et al.   JOURNAL OF NEUROSCIENCE

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY